Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
ABUS 10.23.2024
Drug:AB-729 imdusiran
Drug:None AB-101
Diseases:chronic hepatitis B virus (cHBV) infection
Diseases:chronic hepatitis B virus (cHBV) infection
Date of Upcoming Event:2024-11-06
Name of Upcoming Event:Q3 2024 Conference Call/Webcast
WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast are as follows:
| • Q3 2024 Press Release: | Wednesday, November 6, 2024 at 7:30 a.m. ET |
| • Q3 2024 Conference Call/Webcast: | Wednesday, November 6, 2024 at 8:45 a.m. ET |
To dial-in for the conference call by phone, please register using the following link:Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus' website atwww.arbutusbio.com.
An archived webcast will be available on the Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visitwww.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. CaperelliVice President, Investor RelationsPhone: 215-206-1822Email:lcaperelli@arbutusbio.com
